

To be brigadier general

Col. Jeffrey J. Johnson
Col. Ronald T. Stephens

The following named officers for appointment in the United States Army Medical Service Corps to the grade indicated under title 10, U.S.C., sections 624 and 3064:

To be brigadier general

Col. Dennis P. LeMaster
Col. Michael J. Talley

The following named officer for appointment in the United States Army to the grade indicated while assigned to a position of importance and responsibility under title 10, U.S.C., section 601:

To be lieutenant general

Maj. Gen. Michael K. Nagata

IN THE MARINE CORPS

The following named officers for appointment in the United States Marine Corps Reserve to the grade indicated under title 10, U.S.C., 12203:

To be brigadier general

Col. Bradley S. James
Col. Kurt W. Stein

IN THE ARMY

The following named officer for appointment in the United States Army to the grade indicated while assigned to a position of importance and responsibility under title 10, U.S.C., section 601:

To be lieutenant general

Maj. Gen. Austin S. Miller

NOMINATIONS PLACED ON THE SECRETARY'S DESK

IN THE AIR FORCE

PN1164 AIR FORCE nominations (16) beginning JAMES B. ANDERSON, and ending HYRAL B. WALKER, JR., which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1165 AIR FORCE nominations (14) beginning JEREMY V. BASTIAN, and ending CHRISTOPHER A. WATSON, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1166 AIR FORCE nominations (2068) beginning CHRISTOPHER F. ABBOTT, and ending DEVIN LEE ZUFELT, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1167 AIR FORCE nomination of Christopher T. Stein, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

IN THE ARMY

PN1077 ARMY nomination of Gregory L. Boylan, which was received by the Senate and appeared in the Congressional Record of January 11, 2016.

PN1107 ARMY nomination of Derek G. Bean, which was received by the Senate and appeared in the Congressional Record of January 28, 2016.

PN1168 ARMY nominations (120) beginning ADRIAN R. ALGARRA, and ending GREGORY B. WILLIAMS, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1169 ARMY nominations (50) beginning PHILIP O. ADAMS, and ending BENJAMIN M. WUNDERLICH, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1170 ARMY nominations (27) beginning JULIA N. ALVAREZ, and ending APRIL D. WILLIAMS, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1171 ARMY nominations (178) beginning WENDY M. ADAMIAN, and ending D012433,

which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1172 ARMY nomination of Vernita M. Corbett, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1173 ARMY nominations (44) beginning MATTHEW H. ADAMS, and ending D012453, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1175 ARMY nomination of William D. Rose, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1176 ARMY nomination of Mark W. Manoso, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1177 ARMY nomination of Eric F. Sabety, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1197 ARMY nominations (2) beginning ANDREW R. MCIVER, and ending GERARD C. PHILIP, which nominations were received by the Senate and appeared in the Congressional Record of March 3, 2016.

IN THE FOREIGN SERVICE

PN464 FOREIGN SERVICE nominations (7) beginning Eric Del Valle, and ending Ryan Truxton, which nominations were received by the Senate and appeared in the Congressional Record of May 7, 2015.

PN952 FOREIGN SERVICE nominations (11) beginning Cheryl L. Anderson, and ending Melissa A. Williams, which nominations were received by the Senate and appeared in the Congressional Record of November 19, 2015.

PN953 FOREIGN SERVICE nominations (37) beginning Jennifer M. Adams, and ending Sunil Sebastian Xavier, which nominations were received by the Senate and appeared in the Congressional Record of November 19, 2015.

PN1086 FOREIGN SERVICE nominations (4) beginning Daryl Arthur Brehm, and ending Melinda D. Sallyards, which nominations were received by the Senate and appeared in the Congressional Record of January 19, 2016.

PN1087 FOREIGN SERVICE nominations (23) beginning Scott D. Hocklander, and ending Catherine Mary Trujillo, which nominations were received by the Senate and appeared in the Congressional Record of January 19, 2016.

PN1089 FOREIGN SERVICE nomination of Holly S. Higgins, which was received by the Senate and appeared in the Congressional Record of January 19, 2016.

PN1156 FOREIGN SERVICE nomination of John McCaslin, which was received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1157 FOREIGN SERVICE nominations (11) beginning Laurie Farris, and ending James Rigasio, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

IN THE MARINE CORPS

PN1117 MARINE CORPS nominations (5) beginning AARON R. CRAIG, and ending CHRISTOPHER T. STEINHILBER, which nominations were received by the Senate and appeared in the Congressional Record of January 28, 2016.

PN1130 MARINE CORPS nominations (2) beginning JIMMY W. DARSEY, and ending GERALD E. PIRK, JR., which nominations were received by the Senate and appeared in the Congressional Record of January 28, 2016.

IN THE NAVY

PN1178 NAVY nominations (53) beginning MATTHEW T. ALLEN, and ending JOSHUA

F. ZIMMER, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1179 NAVY nominations (4) beginning RICHARD W. LANG, and ending BRADLEY E. SHEMLUCK, which nominations were received by the Senate and appeared in the Congressional Record of February 22, 2016.

PN1198 NAVY nomination of Michael L. Hipp, which was received by the Senate and appeared in the Congressional Record of March 3, 2016.

PN1200 NAVY nomination of Ronald H. Nellen, which was received by the Senate and appeared in the Congressional Record of March 3, 2016.

PN1202 NAVY nomination of Ashley A. Hockycko, which was received by the Senate and appeared in the Congressional Record of March 3, 2016.

LEGISLATIVE SESSION

The PRESIDING OFFICER. The Senate will now resume legislative session.

ENSURING PATIENT ACCESS AND EFFECTIVE DRUG ENFORCEMENT ACT OF 2015

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the Senate proceed to the immediate consideration of Calendar No. 368, S. 483.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 483) to improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes.

There being no objection, the Senate proceeded to consider the bill, which had been reported from the Committee on the Judiciary, with an amendment to strike all after the enacting clause and insert in lieu thereof the following:

SECTION 1. SHORT TITLE.

This Act may be cited as the "Ensuring Patient Access and Effective Drug Enforcement Act of 2016".

SEC. 2. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.*(a) DEFINITIONS.—*

(1) FACTORS AS MAY BE RELEVANT TO AND CONSISTENT WITH THE PUBLIC HEALTH AND SAFETY.—Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:

"(j) In this section, the phrase 'factors as may be relevant to and consistent with the public health and safety' means factors that are relevant to and consistent with the findings contained in section 101."

(2) IMMINENT DANGER TO THE PUBLIC HEALTH OR SAFETY.—Section 304(d) of the Controlled Substances Act (21 U.S.C. 824(d)) is amended—

(A) by striking "(d) The Attorney General" and inserting "(d)(1) The Attorney General"; and

(B) by adding at the end the following:

"(2) In this subsection, the phrase 'imminent danger to the public health or safety' means that, due to the failure of the registrant to maintain effective controls against diversion or otherwise comply with the obligations of a registrant under this title or title III, there is a substantial likelihood of an immediate threat that death, serious bodily harm, or abuse of a controlled substance will occur in the absence of an immediate suspension of the registration."

(b) OPPORTUNITY TO SUBMIT CORRECTIVE ACTION PLAN PRIOR TO REVOCATION OR SUSPENSION.—Subsection (c) of section 304 of the Controlled Substances Act (21 U.S.C. 824) is amended—

(1) by striking the last three sentences;
 (2) by striking “(c) Before” and inserting “(c)(1) Before”; and
 (3) by adding at the end the following:
 “(2) An order to show cause under paragraph (1) shall—

“(A) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated by the applicant or registrant;

“(B) direct the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but not less than 30 days after the date of receipt of the order; and
 “(C) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before the date of appearance.

“(3) Upon review of any corrective action plan submitted by an applicant or registrant pursuant to paragraph (2), the Attorney General shall determine whether denial, revocation, or suspension proceedings should be discontinued, or deferred for the purposes of modification, amendment, or clarification to such plan.

“(4) Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of chapter 5 of title 5, United States Code. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States.

“(5) The requirements of this subsection shall not apply to the issuance of an immediate suspension order under subsection (d).”

SEC. 3. REPORT TO CONGRESS.

(a) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Agency for Healthcare Research and Quality, and the Director of the Centers for Disease Control and Prevention, in coordination with the Administrator of the Drug Enforcement Administration and in consultation with the Secretary of Defense and the Secretary of Veterans Affairs, shall submit a report to the Committee on the Judiciary of the House of Representatives, the Committee on Energy and Commerce of the House of Representatives, the Committee on the Judiciary of the Senate, and the Committee on Health, Education, Labor, and Pensions of the Senate identifying—

(1) obstacles to legitimate patient access to controlled substances;

(2) issues with diversion of controlled substances;

(3) how collaboration between Federal, State, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances;

(4) the availability of medical education, training opportunities, and comprehensive clinical guidance for pain management and opioid prescribing, and any gaps that should be addressed;

(5) beneficial enhancements to State prescription drug monitoring programs, including enhancements to require comprehensive prescriber input and to expand access to the programs for appropriate authorized users; and
 (6) steps to improve reporting requirements so that the public and Congress have more information regarding prescription opioids, such as the volume and formulation of prescription opioids prescribed annually, the dispensing of such prescription opioids, and outliers and trends within large data sets.

(b) CONSULTATION.—The report under subsection (a) shall incorporate feedback and recommendations from the following:

(1) Patient groups.

(2) Pharmacies.

(3) Drug manufacturers.

(4) Common or contract carriers and warehousemen.

(5) Hospitals, physicians, and other health care providers.

(6) State attorneys general.

(7) Federal, State, local, and tribal law enforcement agencies.

(8) Health insurance providers and entities that provide pharmacy benefit management services on behalf of a health insurance provider.

(9) Wholesale drug distributors.

(10) Veterinarians.

(11) Professional medical societies and boards.

(12) State and local public health authorities.

(13) Health services research organizations.

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the committee-reported substitute amendment be agreed to, the bill, as amended, be read a third time and passed, and the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The committee-reported amendment in the nature of a substitute was agreed to.

The bill (S. 483), as amended, was ordered to be engrossed for a third reading, was read the third time, and passed.

PROVIDING AUTHORITY TO MAINTAIN AND OPERATE A TOLL BRIDGE ACROSS THE RIO GRANDE

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the Senate proceed to the immediate consideration of Calendar No. 374, S. 2143.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 2143) to provide for the authority for the successors and assigns of the Starr-Camargo Bridge Company to maintain and operate a toll bridge across the Rio Grande near Rio Grande City, Texas, and for other purposes.

There being no objection, the Senate proceeded to consider the bill.

Mr. MCCONNELL. I ask unanimous consent that the bill be read a third time and passed and the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (S. 2143) was ordered to be engrossed for a third reading, was read the third time, and passed, as follows:
 S. 2143

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. STARR-CAMARGO BRIDGE.

Public Law 87-532 (76 Stat. 153) is amended—

(1) in the first section, in subsection (a)(2)—

(A) by inserting “, and its successors and assigns,” after “State of Texas”;

(B) by inserting “consisting of not more than 14 lanes” after “approaches thereto”; and

(C) by striking “and for a period of sixty-six years from the date of completion of such bridge.”;

(2) in section 2, by inserting “and its successors and assigns,” after “companies”;

(3) by redesignating sections 3, 4, and 5 as sections 4, 5, and 6, respectively;

(4) by inserting after section 2 the following:

“SEC. 3. RIGHTS OF STARR-CAMARGO BRIDGE COMPANY AND SUCCESSORS AND ASSIGNS.

“(a) IN GENERAL.—The Starr-Camargo Bridge Company and its successors and assigns shall have the rights and privileges granted to the B and P Bridge Company and its successors and assigns under section 2 of the Act of May 1, 1928 (45 Stat. 471, chapter 466).

“(b) REQUIREMENT.—In exercising the rights and privileges granted under subsection (a), the Starr-Camargo Bridge Company and its successors and assigns shall act in accordance with—

“(1) just compensation requirements;

“(2) public proceeding requirements; and

“(3) any other requirements applicable to the exercise of the rights referred to in subsection (a) under the laws of the State of Texas.”; and

(5) in section 4 (as redesignated by paragraph (3))—

(A) by inserting “and its successors and assigns,” after “such company”;

(B) by striking “or” after “public agency.”;

(C) by inserting “or to a corporation,” after “international bridge authority or commission.”; and

(D) by striking “authority, or commission” each place it appears and inserting “authority, commission, or corporation”.

ADDING ZIKA VIRUS TO THE FDA PRIORITY REVIEW VOUCHER PROGRAM ACT

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the Senate proceed to the immediate consideration of Calendar No. 389, S. 2512.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 2512) to expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

There being no objection, the Senate proceeded to consider the bill, which had been reported from the Committee on Health, Education, Labor, and Pensions, with an amendment to strike all after the enacting clause and insert in lieu thereof the following:

SECTION 1. SHORT TITLE.

This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.

SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1) by redesignating subparagraph (R) as subparagraph (S);

(2) in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and

(3) by inserting after subparagraph (Q) the following:

“(R) Zika Virus Disease.”.

Mr. MCCONNELL. I ask unanimous consent that the committee-reported substitute amendment be agreed to, the bill, as amended, be read a third time and passed, and the motion to reconsider be considered made and laid upon the table.